课题基金 / 基金详情

Electrophysiological and morphological study of endolymphatic sac

Electrophysiological and morphological study of endolymphatic sac
内淋巴囊的电生理和形态学研究
批准号:
02670766
负责人:
MORI Nozomu
金额:
$1.54万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1990
资助国家:
日本
项目状态:
已结题
起止时间:
1990 至 1991

项目摘要

项目成果

MORI Nozomu的其他基金

相似基金

相关文献

中文摘要
翻译
(电生理研究)用玻璃微电极测定豚鼠内淋巴囊直流电电位,考察缺氧和各种药物对内淋巴囊直流电电位的影响,了解其性质。结果表明:1)ESP由缺氧敏感部分和缺氧敏感部分组成。2)醛固酮拮抗剂canrenate以剂量依赖性的方式降低ESP。3)乙酰唑胺,一种碳酸酐酶抑制剂,在ESP中产生剂量依赖性的下降,在大剂量时其作用达到饱和。4)儿茶酚胺通过β -肾上腺素能作用可逆地降低ESP。5) ESP的缺氧敏感部分由儿茶酚胺敏感部分和乙酰唑胺敏感部分组成。(形态学研究)观察小鼠内淋巴囊的超微结构及大分子在内淋巴囊中的转运情况。结果表明:1)小鼠ES分为近端、中端和远端三部分。2)中间部分上皮细胞分为I型和II型两种类型。I型细胞具有丰富的微绒毛、胞饮泡、液泡、多泡体、溶酶体和线粒体。II型细胞中这些细胞器的数量较少。3) ES毛细血管分为有孔毛细血管和无孔毛细血管。它们都被认为是大分子可渗透的。ES上皮的基底外侧吸收被认为是活跃的,特别是在中间部分。
英文摘要
(Electrophysiological Study)The endolymphatic sac direct current potential(ESP)was measured in the guinea pig by means of a glass microelectrode, and the effect of anoxia and various agents on the ESP was examined to know its properties. The results are as follows : 1)The ESP is composed of an anoxia-sensitive part and an anoxiainsensitive part. 2)Canrenoate, an aldosterone antagonist, decreased the ESP in a dose-dependent manner. 3)Acetazolamide, a carbonic anhydrase inhibitor, produced a dose-dependent decrease in the ESP with a saturation of its effect at large doses. 4)Catecholamines reversibly decreased the ESP by beta-adrenergic action. 5)The anoxia-sensitive part of the ESP consists of catecholamine-sensitive and acetazolamide-spnsitve parts.(Morphological Study)Ultrastructure of the endolymphatic sac(ES)in the mouse and the transport of macromolecule in the ES were observed. The results are as follows : 1)The ES in the mouse was divided into three parts : proximal, intermediate and distal. 2)The epithelial cells in the intermediate portion were classified into two types : type I and type II. Type I cells had abundant microvilli, pinocytotic vesicles, vacuoles, multivesicular bodies, lysosomes and mitochondria. Type II cells had fewer numbers of these organelles. 3)The capillaries of the ES were classified as either fenestrated or non-fenestrated. They were botn considered to be permeable to macromolecules. The basolateral absorption in the ES epithelium was considered to be active especially in the intermediate portion.
期刊论文(23)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
N.Mori,and N.Uozumi: "Evidence that β_2 receptors mediate the action of catecholamines on the endolymphatic sac DC potential" Am.J.Physiol.260. R911-R915 (1991)
N.Mori 和 N.Uozumi:“β_2 受体介导儿茶酚胺对内淋巴囊 DC 电位作用的证据”Am.J.Physiol.260 (1991)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
N.Mori,N.Uozumi,K.Yura,and S.Sakai: "The difference in endocochlear and endolymphatic sac d.c.potentials in response to furosemide and canrenoate as diuretics" Eur.Arch.Otorhinolaryngol.247. 371-373 (1990)
N.Mori、N.Uozumi、K.Yura 和 S.Sakai:“速尿和坎雷诺酸利尿剂对耳蜗内和内淋巴囊直流电势的差异”Eur.Arch.Otorhinolaryngol.247。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 19 条
    Regulatory roles of NRSF/REST variants in the aging brain
    • 批准号:
      15K14352
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2015
    • 负责人:
      MORI Nozomu
    • 依托单位:
    Establishment of an in vitro aging system of non-dividing cells
    • 批准号:
      24650200
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2012
    • 负责人:
      MORI Nozomu
    • 依托单位:
    Positive and negative regulations of cytoskeletal dynamism and neuronal lifespan
    • 批准号:
      22300121
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.65万
    • 财政年份:
      2010
    • 负责人:
      MORI Nozomu
    • 依托单位:
    Research on the role of βadrenergic receptors in pathogenesis of Meniere's disease
    • 批准号:
      22591883
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2010
    • 负责人:
      MORI Nozomu
    • 依托单位:
    海外基金